Compare · GILD vs MAZE
GILD vs MAZE
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.55B, about 104.8x MAZE ($1.53B).
- Over the past year, GILD is up 14.5% and MAZE is up 67.1% - MAZE leads by 52.7 points.
- GILD has hit the wire 6 times in the past 4 weeks while MAZE has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- Gilead Sciences Inc.
- Maze Therapeutics Inc.
- Price
- $129.35-1.16%
- $27.66+0.04%
- Market cap
- $160.55B
- $1.53B
- 1M return
- +3.36%
- +3.83%
- 1Y return
- +14.46%
- +67.13%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2025
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 7
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
Latest MAZE
- President, R&D & CMO Bernstein Harold exercised 14,609 shares at a strike of $10.42 and sold $436,864 worth of shares (14,609 units at $29.90) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Coloma Jason V sold $1,034,253 worth of shares (34,501 units at $29.98) as part of a pre-agreed trading plan (SEC Form 4)
- CSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $210,150 worth of shares (7,500 units at $28.02) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Maze Therapeutics Inc.
- Chief Executive Officer Coloma Jason V sold $725,495 worth of shares (27,858 units at $26.04) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Director Spiegelman Daniel K
- SEC Form 4 filed by Director Scheller Richard H
- SEC Form 4 filed by Director Lim Jonathan E
- SEC Form 4 filed by Director Hoppenot Herve
- SEC Form 4 filed by Director Homcy Charles J